What RevMed’s pancreatic cancer drug meant for one patient

The Readout LOUD What RevMed’s pancreatic cancer drug meant for one patient Manage alerts for this article Email this article Share this article By Elaine Chen, Adam Feuerstein, and Allison DeAngelisJune 4, 2026 Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.Adam Feuerstein[email protected]Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.Allison DeAngelis[email protected]Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01. Why did oncologists give a standing ovation to a data presentation on Revolution Medicines’ pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this week? And are concrete beaches better than normal beaches? We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.Advertisement We bring on Leanna Stokes, who was diagnosed with metastatic pancreatic cancer in 2023. She discusses how participating in RevMed’s trial for daraxonrasib has affected her disease and life, and what the drug means for patients and the field. We also chat about other data presented during last week’s meeting of the American Society of Clinical Oncology, the market reaction to Abivax’s ulcerative colitis data, and the upcoming meeting of the American Diabetes Association. For more on RevMed’s data presented at ACSO, go here; to read more on Leanna’s story, go here. For more on our other ASCO coverage, go here. To read more on Abivax’s readout, go here; and to sign up for our coverage of the ADA meeting, go here.Advertisement Be sure to sign up for “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts. ASCO, biotechnology, Cancer, diabetes Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Adam Feuerstein Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54. Allison DeAngelis Biotech Startups and Venture Capital Reporter Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis.01. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech May 28, 2026 STAT Plus: Biotech veteran Jeremy Levin on why the industry’s future is secure, but American leadership is at risk The Readout LOUD May 28, 2026 Biotech exec Jeremy Levin on the industry’s strategic turning point Advertisement The Readout LOUD May 21, 2026 Guarding biotech from China and big bets in longevity The Readout LOUD May 14, 2026 Makary’s departure and Cassidy’s tenuous Senate seat The Readout LOUD May 7, 2026 Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles Subscriber Picks